



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

19 February 2021

DEPARTMENT MEMORANDUM


No. 2021- 0097

**FOR: ALL DIRECTORS OF BUREAUS AND REGIONAL OFFICES, BARMM
MINISTER OF HEALTH; CHIEFS OF MEDICAL CENTERS, HOSPITALS
AND SANITARIA, AND OTHERS CONCERNED**

**SUBJECT: Health Technology Assessment Council's (HTAC) Recommendations
on COVID-19 health technologies**

By virtue of Republic Act 11223, otherwise known as the Universal Health Care (UHC) Act, health technology assessment (HTA) shall be institutionalized as a fair and transparent priority-setting mechanism to provide financing and coverage recommendations on health technologies to be funded by the Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth). In light of the public health emergency, the HTA Council (HTAC) aims to generate evidence-informed health technology recommendations amidst rapidly evolving evidence. As such, please be informed that the Secretary of Health has approved the final HTAC recommendations on the following COVID-19 health technologies:

1. AMTI uAI-Discover-PNA (Pneumonia) to facilitate diagnosis, assessment, and staging of COVID-19
2. Cycloferon® for the treatment of COVID-19
3. Extracorporeal Machine Oxygenation (ECMO) for patients with Acute Respiratory Distress Syndrome (ARDS) in COVID-19
4. Favipiravir for the treatment of COVID-19
5. High-Flow Nasal Cannula (HFNC) Oxygen Therapy for the treatment of Acute Hypoxemic Respiratory Failure for COVID-19
6. Huawei Cloud Artificial Intelligence (AI)-Assisted Diagnosis for COVID-19
7. IgG and IgM Rapid Diagnostic Test (RDT) Kits for Mild and Asymptomatic At-Risk COVID-19 Cases
8. Rapid Antibody-based Test Kits (RATs) for Various Use Cases for COVID-19
9. SARS-CoV-2 RT-PCR Test Kits for the Diagnosis of COVID-19 Cases
10. Pooled Testing for the Diagnosis, Screening, and Surveillance of COVID-19
11. Rapid Antigen Test Kits for the diagnosis of COVID-19
12. Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19
13. AstraZeneca COVID-19 Vaccine for the prevention of COVID-19



To view the full evidence summary and rapid review of these recommendations, you may visit the HTA website at hta.doh.gov.ph.

For your information and guidance.

By Authority of the Secretary of Health:



GERARDO V. BAYUGO, MD, MPH, CESO I
Undersecretary of Health
Health Regulation Team

